within Pharmacolibrary.Drugs.ATC.B;

model B01AB09
  extends Pharmacokinetic.Models.PK_2C(
    weight         = 70,
    F              = 1,
    Cl             = 1.9999999999999998e-05,
    adminDuration  = 600,
    adminMass      = 750 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0043,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,            
    Vdp             = 0.0075,
    k12             = 0.62,
    k21             = 0.62
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>B01AB09</td></tr><td>route:</td><td>subcutaneous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Danaparoid is a low molecular weight heparinoid anticoagulant, composed of a mixture of glycosaminoglycans, primarily used as an alternative anticoagulant in patients with heparin-induced thrombocytopenia (HIT). It is administered parenterally. Though previously widely used, its availability has become limited in some regions due to regulatory and supply issues.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetics in healthy adult volunteers and patients; based on published data of anti-factor Xa activity after intravenous and subcutaneous administration.</p><h4>References</h4><ol><li><p>Garcia, DA, et al., &amp; Samama, MM (2012). Parenteral anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. <i>Chest</i> 141(2 Suppl) e24S–e43S. DOI:<a href=&quot;https://doi.org/10.1378/chest.11-2291&quot;>10.1378/chest.11-2291</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/22315264/&quot;>https://pubmed.ncbi.nlm.nih.gov/22315264</a></p></li><li><p>Ibbotson, T, &amp; Perry, CM (2002). Danaparoid: a review of its use in thromboembolic and coagulation disorders. <i>Drugs</i> 62(15) 2283–2314. DOI:<a href=&quot;https://doi.org/10.2165/00003495-200262150-00016&quot;>10.2165/00003495-200262150-00016</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/12381232/&quot;>https://pubmed.ncbi.nlm.nih.gov/12381232</a></p></li><li><p>Danhof, M, et al., &amp; Stiekema, JC (1992). Pharmacokinetic considerations on Orgaran (Org 10172) therapy. <i>Haemostasis</i> 22(2) 73–84. DOI:<a href=&quot;https://doi.org/10.1159/000216298&quot;>10.1159/000216298</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/1379967/&quot;>https://pubmed.ncbi.nlm.nih.gov/1379967</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end B01AB09;
